MYNZ

Mainz Biomed B.V. (NASDAQ:MYNZ) is a German molecular genetics diagnostic company founded in 2008 and based in Mainz, Germany. The company went public on November 5, 2021, and specializes in developing in-vitro diagnostic tests and research tools for cancer screening and pathogen detection. As a clinical-stage biotechnology company, Mainz Biomed focuses on creating molecular genetic tests that can detect cancer biomarkers and other genetic indicators from biological samples, primarily targeting early-stage cancer detection where traditional screening methods may be less effective.